Health Services Stocks On The Rise With Help From 3 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 16,507 as of Monday, Aug. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,334 issues advancing vs. 1,665 declining with 161 unchanged.

The Health Services industry currently sits down 0.2% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Grifols ( GRFS), up 1.5%, Humana ( HUM), up 1.1%, Edwards Lifesciences ( EW), up 1.0%, CR Bard ( BCR), up 0.9% and Boston Scientific ( BSX), up 0.8%. On the negative front, top decliners within the industry include Alere ( ALR), down 13.5%, and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Express Scripts ( ESRX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Express Scripts is up $0.36 (0.5%) to $70.52 on light volume. Thus far, 1.9 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $69.93-$70.74 after having opened the day at $70.00 as compared to the previous trading day's close of $70.17.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. The company offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $51.9 billion and is part of the health care sector. Shares are down 0.1% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Express Scripts Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Covidien ( COV) is up $0.68 (0.8%) to $87.61 on light volume. Thus far, 1.3 million shares of Covidien exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $86.71-$87.66 after having opened the day at $86.93 as compared to the previous trading day's close of $86.93.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $39.1 billion and is part of the health care sector. Shares are up 27.6% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Covidien a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Medtronic ( MDT) is up $0.54 (0.9%) to $62.02 on light volume. Thus far, 2.8 million shares of Medtronic exchanged hands as compared to its average daily volume of 8.0 million shares. The stock has ranged in price between $61.20-$62.11 after having opened the day at $61.60 as compared to the previous trading day's close of $61.48.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. Medtronic has a market cap of $61.5 billion and is part of the health care sector. Shares are up 7.1% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Medtronic a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Medtronic Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC